U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C25H30ClN5O3.C6H8O4
Molecular Weight 628.116
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of BERADILOL MONOETHYL MALEATE

SMILES

CCOC(=O)\C=C/C(O)=O.CC1CC(=O)NN=C1C2=CC=C(NCC(C)(C)NCC(O)COC3=CC(Cl)=CC=C3C#N)C=C2

InChI

InChIKey=TZXOVBAUUXGKJG-QGAMPUOQSA-N
InChI=1S/C25H30ClN5O3.C6H8O4/c1-16-10-23(33)30-31-24(16)17-5-8-20(9-6-17)28-15-25(2,3)29-13-21(32)14-34-22-11-19(26)7-4-18(22)12-27;1-2-10-6(9)4-3-5(7)8/h4-9,11,16,21,28-29,32H,10,13-15H2,1-3H3,(H,30,33);3-4H,2H2,1H3,(H,7,8)/b;4-3-

HIDE SMILES / InChI
Molecular Formula C25H30ClN5O3
Molecular Weight 483.99
Charge 0
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula C6H8O4
Molecular Weight 144.1253
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/9147023,9468640,7912931

TZC-5665 (Oberadilol) is a pyridazinone derivative with vasodilatory and beta-adrenergic blocking activities and type III phosphodiesterase inhibitory action

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Cardiac effects of the novel pyridazinone derivative 6-[4-[2-[3-(5-chloro-2-cyanophenoxy)-2-hydroxypropylamino]- 2- methylpropylamino]phenyl]-4,5-dihydro-5-methyl-3(2H) pyridazinone monoethyl maleate and its metabolite in isolated heart preparations of guinea pigs and dogs.
1994 May
Cardiac and hemodynamic effects of TZC-5665, a novel pyridazinone derivative, and its metabolite in humans and dogs.
1997 Apr
Studies on agents with vasodilator and beta-blocking activities. V. Synthesis and pharmacological activity of the optical isomers of TZC-5665.
1998 Jan
Patents

Patents

JPS63183568A
2

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Orally administered TZC-5665 reduced end-diastolic left ventricular volume and exhibited a tendency to increase ejection fraction.
Unknown
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 06:19:13 GMT 2023
Edited
by admin
on Sat Dec 16 06:19:13 GMT 2023
Record UNII
9G211L8M9H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BERADILOL MONOETHYL MALEATE
JAN  
Common Name English
BERADILOL MONOETHYL MALEATE [JAN]
Common Name English
BENZONITRILE, 4-CHLORO-2-(3-((1,1-DIMETHYL-2-((4-(1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)PHENYL)AMINO)ETHYL)AMINO)-2-HYDROXYPROPOXY)-, MONO(ETHYL (2Z)-2-BUTENEDIOATE) (SALT)
Common Name English
TZC-5665
Common Name English
OBERADILOL MONOETHYL MALEATE
Common Name English
Code System Code Type Description
PUBCHEM
6449836
Created by admin on Sat Dec 16 06:19:13 GMT 2023 , Edited by admin on Sat Dec 16 06:19:13 GMT 2023
PRIMARY
CAS
114856-47-2
Created by admin on Sat Dec 16 06:19:13 GMT 2023 , Edited by admin on Sat Dec 16 06:19:13 GMT 2023
PRIMARY
FDA UNII
9G211L8M9H
Created by admin on Sat Dec 16 06:19:13 GMT 2023 , Edited by admin on Sat Dec 16 06:19:13 GMT 2023
PRIMARY
Related Record Type Details
Structure of OBERADILOL
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of OBERADILOL
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966